logo-loader
viewBrainStorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics looks forward to top-line results for its ALS Phase 3 program

BrainStorm Cell Therapeutics (NASDAQ:BCLI) COO and Chief Medical Officer Ralph Kern sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The biotech is focused on generating top-line results for its ALS Phase 3 and progressive MS Phase 2 trials in Q4 2020 to gain eventual commercialization of its therapy called NurOwn in ALS.

Quick facts: BrainStorm Cell Therapeutics Inc.

Price: 12.79 USD

NASDAQ:BCLI
Market: NASDAQ
Market Cap: $403.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

1 day, 19 hours ago

2 min read